Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
AND EXCHANGE COMMISSION
to Section 13 or 15(d)
the Securities Exchange Act of 1934
of Report (Date of earliest event reported): January 21, 2021
name of registrant as specified in its charter)
Recreation Park Drive, Unit 108
of Principal Executive Offices) (Zip Code)
telephone number, including area code: (781) 875-3605
Name or Former Address, if Changed Since Last Report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on which registered
Stock, $0.01 par value
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Growth Company [ ]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
January 21, 2021, Microbot Medical Inc. (the “Company”) issued a press release announcing that the Company continues
to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members:
B. Solomon, MD, a board-certified radiologist with clinical expertise in Interventional Radiology with a focus in Tumor Ablation;
K. Wakhloo, MD PhD FAHA, an internationally recognized expert in acute stroke therapy and the isolation of intracranial aneurysms
and arteriovenous malformations;
Yaniv, MD, PhD, an endovascular neurosurgeon and leading authority on Artificial Intelligence;
J. Rabkin, MD, PhD, FSIR, a vascular and Interventional Radiology Specialist; and
Neeman, MD, a vascular and interventional radiology clinician and researcher with a wide array of expertise, particularly
in the field of navigation systems for minimally invasive image-guided interventional procedures.
press release furnished as Exhibit 99.1 to this Current Report on Form 8-K are incorporated herein by reference. The information
in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Statements and Exhibits.
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Executive Officer, President and Chairman
Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders
Mass., January 21, 2021 – Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities
with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist
with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K. Wakhloo, MD PhD FAHA, an internationally
recognized expert in acute stroke therapy and the isolation of intracranial aneurysms and arteriovenous malformations; Gal Yaniv,
MD, PhD, an endovascular neurosurgeon and leading authority on Artificial Intelligence; Dmitry J. Rabkin, MD, PhD, FSIR, a vascular
and Interventional Radiology Specialist; and Ziv Neeman, MD, a vascular and interventional radiology clinician and researcher
with a wide array of expertise, particularly in the field of navigation systems for minimally invasive image-guided interventional
we continue to develop and perfect our novel technologies, it remains critical that we also attract extraordinary capabilities
throughout the organization – management, Board of Directors and Scientific Advisory Board – to leverage their combined expertise
to achieve Microbot Medical’s objectives,” commented Harel Gadot, CEO, President and Chairman. “We are expecting
a higher level of activity in the next year, including significant clinical and regulatory milestones, so our ability to attract
leading talent and capitalize on their successes should enable us to maintain a competitive advantage and be at the forefront
of developing innovative technologies to address the healthcare industry’s unmet medical needs.”
B. Solomon, MD is Chief of the Interventional Radiology Service at Memorial Sloan Kettering, where he also holds the Enid
A. Haupt Chair in Clinical Investigation. He is Director of Memorial Sloan Kettering’s Center for Image-Guided Interventions
and leads a research lab that works to improve image-guided cancer interventions. He treats kidney cancer, liver cancer, lung
cancer and bone cancer, has an interest in treating tumors with thermal ablation and performs hepatic artery embolization.
Dr. Solomon was named a Castle Connolly: New York Magazine Top Doctor from 2012-2013 and 2015-2020. He received his undergraduate
degree from Harvard, medical degree from Yale School of Medicine, and completed residencies at Yale-New Haven Hospital and
The John Hopkins Hospital.
Yaniv, MD, PhD is a founder and the Chief Medical Officer at Aidoc, contributing his expertise and knowledge to help in
the continuing development of advanced, healthcare grade AI. He is currently the Director, Endovascular Neurosurgery unit
at Sheba – Tel HaShomer hospital. A double graduate (M.D, PhD, cum laude on both) of the Technion – Israel Institute
of Technology, Dr. Yaniv completed his radiology residency at Sheba, Tel HaShomer hospital as well as diagnostic neuroradiology
fellowship at Yale School of Medicine and endovascular neurosurgery fellowship at Mount Sinai Hospital. He has published numerous
scientific publications focusing on basic science, radiology and public health, including a recent publication at the New
England Journal of Medicine, and has presented in various scientific conferences worldwide. As a “Talpiot” alumni,
he participates in the “Talpiot Medical Leadership Program” at Tel HaShomer Hospital.
J. Rabkin, MD, PhD, FSIR is a Vascular and Interventional Radiology Specialist, who is currently the Assistant Professor
of Radiology at the Harvard Medical School and Assistant Chief of the Division of Interventional Radiology at the Brigham
and Women’s Hospital. Previously, he was a Clinical Director and Chief of the Division of Interventional Radiology at
the Beth Israel Deaconess Medical Center, HMS, where he completed his residency in Diagnostic Radiology and a fellowship in
Vascular and Interventional Radiology. He graduated from the First Moscow Medical School. Based on his achievements and contributions
to the specialty, Dr. Rabkin has been elected to Fellowship of the Society of Interventional Radiology. Dr. Rabkin has been
recognized as a Castle Connolly Top Doctor and Boston Magazine Top Doctor since 2016 for his professional qualifications,
reputation and clinical skills in the field of Interventional Radiology.
K. Wakhloo, MD PhD FAHA is certified by the American Board of Radiology in Neuroradiology and Diagnostic Radiology, and
he currently serves as Chief of Neurointerventional Radiology and Professor at TUFTS University School of Medicine. Prior
to Tufts, he was a tenured Professor of Radiology, Neurology and Neurosurgery and the Director, Division NeuroImaging and
Intervention (NII) in the Department of Radiology, University of Massachusetts Medical School. Earlier in his career, Dr.
Wakhloo was a tenured Professor of Radiology, Neurological Surgery and Biomedical Engineering in the Department of Radiology
at the University of Miami, Miller School of Medicine. He received both his medical degree and Ph.D. from the University of
Mainz, Germany and completed his Internship and Residency in Internal Medicine at the University of Mainz. His training was
continued at the University of Freiburg, Germany in diagnostic and interventional Neuroradiology. He also completed fellowships
in Neurosurgery at the University of Freiburg and Endovascular Neurosurgery at SUNY Buffalo, as well as Research Fellowships
in Neurological Surgery at Barrow Neurological Institute and in Neurosurgery at SUNY Buffalo.
Neeman, MD is the Director of the Diagnostic Imaging Institute and Nuclear Medicine at the Haemek Medical Center (Afula,
Israel). He is affiliated with the Ruth & Bruce Rapport Faculty of Medicine (Technion, Israel) as Clinical Assistant Professor
in the Diagnostic Radiology Department, where he trains medical students in the field of Diagnostic Imaging. He also serves
as a guideline task force member for the European Society of Gastrointestinal Endoscopy. Dr. Neeman completed fellowships
at Beth Israel Deaconess (Abdominal Imaging) and Georgetown University medical center (Interventional radiology). Prior clinical
roles include Section Chief of Interventional Oncology in the Diagnostic Radiology Department at the National Institutes of
Health (NIH) Clinical Center (Bethesda, MD), and Chairman of the Diagnostic Imaging Institute at the Haemek Medical Center.
He was a partner at Diagnostic Imaging Inc. (Philadelphia, PA), where he practiced vascular and interventional radiology,
interventional oncology and diagnostic radiology. He has held academic appointments in the Diagnostic Radiology Departments
at both the NIH, and the University of Maryland Medical Center (Baltimore, MD). Over the span of his career, Dr. Neeman has
published dozens of academic and clinical research articles in peer reviewed journals and serves as an ad hoc reviewer. He
is a graduate of Ben Gurion University of the Negev Faculty of Health Sciences medical school, and completed an Abdominal
Imaging fellowship at the Beth Israel Deaconess Medical Center (affiliated to the Harvard Medical School), Boston, MA and
an Interventional and Vascular Radiology fellowship at the Georgetown University Medical Center, Washington, D.C, and is currently
a member of the Israel Medical Association, the Israel Radiology Association and the Radiological Society of North America
new SAB members join a renowned panel of neurosurgeons and thought leaders in robotic medical technologies, including Prof. Moshe
Shoham. Prof. Shoham is the co-founder of Microbot Medical and founder of Mazor Robotics. The Company believes that the combined
contributions from their diverse sets of expertise will help drive development of next generation robotic endoluminal surgery
devices targeting the minimally invasive surgery space.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY™
and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results
of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic,
need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing
Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed
with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.